News

Penn's David Fajgenbaum, M.D., MBA, is branching out from Castleman disease to assemble comprehensive registry of drugs to treat COVID-19.

COVID-19 has applied a type of pressure on the U.S. this year that none of us have experienced in our lifetimes. Like every other segment of healthcare professionals, certified physician assistants have been put to the test during 2020.

The COVID-19 outbreak has tried the souls of people the world over, both personally and professionally, and healthcare executives are no exception. Despite seeing their plans and schedules torn up, executives can meet and master the unrelenting demands of leadership when a typical workday is anything but. Consider these tips from your industry peers to not just survive but also thrive — and to inspire your employees to do the same.

Farzad Mostashari and Ezekiel Emanuel agree: The COVID-19 experience could be what finally weans American healthcare off of its dependence on fee-for-service payment. But they have a slightly different vocabulary and different notions about what might lead to a tipping point.

COVID-19 forced a shift to virtual behavioral health therapy. Some once-skeptical providers, however, are finding telehealth beneficial. Reimbursement and continued relaxation of regulations will determine whether it’s here to stay.

John D'Amore, president and co-founder for Diameter Health, speaks with Managed Healthcare Executive Senior Editor, Peter Wehrwein, about fast healthcare interoperability resources standards , or FHIR, as they apply to insurers. There are new CMS FHIR regulations for Medicare Advantage and Medicaid managed care plans that go into effect in July 2021. Private insurers are expected to follow suit.

Strategic partnership combines software-as-a-service platform with locum tenens staffing to empower healthcare organizations of all sizes to measure, pinpoint and address clinician burnout.

Hospitals have bounced back from April but are still behind from where they were in May 2019.

One way the federal government responded to the COVID-19 pandemic was to temporarily increase the federal Medicaid matching rate by 6.2 percentage points. In exchange, states couldn’t add restrictions to eligibility and had to offer COVID-19 testing and treatment without cost sharing.

Demand for medications needed for patients who were intubated or put on a ventilator led to some shortages. The CARES Act has some provisions that may help deal with long-standing causes of the drug shortages that plague U.S. healthcare.

Early studies from China suggested that CT scans of the lungs could be used to diagnose the disease. But as PCR tests became available, radiology groups said CT scans should be used more sparingly and in confirmed cases.

A new handbook for facility managers and building owners offers in-depth guidance for how to ensure HVAC systems are properly maintained and upgraded to minimize virus spread.

These are the top 3 drugs recently approved — or soon to be approved by FDA — to watch in 2020.

A new report from the U.C. Berkeley Labor Center and Working Partnerships USA released today shows how technology is likely to impact job quality in healthcare and suggests that technological adoption may accelerate as a result of the COVID-19 pandemic.

Investigational treatment will target marginal zone lymphoma (MZL) and follicular lymphoma (FL).

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year. 

Pharmacy benefit managers are taking steps to be more responsible for the total cost of care and to become more transparent, while adding technology tools to support patients, payers and physicians in a post-COVID-19 world.

The "conservative estimate" assumes that disruption of services ends in six months.

As the pandemic enters its fourth month in the U.S., the Center for Medicare and Medicaid Innovation (the Innovation Center) has announced several changes that, on the whole, increase flexibility for program participants.

Early detection of low blood oxygen levels may detect ‘silent hypoxia’ seen in some patients with COVID-19. But the American Lung Association advises against buying a pulse oximeter unnecessarily.

Payers have used accumulators and maximizers to counteract drug coupons.

Will produce recommendations for policymakers on crucial issues for future of remote care services.

Some hospitals were overwhelmed. But for many providers, COVID-19 has meant the absence of patients - and major drops in revenue. And now there is a possible economic downturn. COVID-19 has hit American healthcare and hit it hard.   

John S. Linehan of Epstein Becker & Green provides an in-depth analysis of drug coupons, coupon accumulators and maximizers and the federal government's halting efforts to regulate them.

John Kalamaras, business intelligence analytics manager of DataGen, chats with Managed Healthcare Executive's Briana Contreras, about the Centers for Medicare and Medicaid Services, or CMS’, recent announcement of the changes they’ve made for participants in their value-based programs, specifically those in bundled-care programs like BPCI Advanced, whose episodes were affected by COVID-19.

A safe, effective vaccine by December 2020 or January 2021?